Lauren Averett Byers

Dec 31, 2024 | journals.lww.com | Lauren Averett Byers

The San Antonio Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR) honored two researchers for their significant contributions to breast cancer research at the 2024 SABCS. Steffi Oesterreich, PhD, is the recipient of the 2024 AACR Distinguished Lectureship in Breast Cancer Research.

Dec 11, 2024 | eurekalert.org | Lauren Averett Byers

Identifying novel therapeutic strategies and making fundamental discoveries related to small cell lung cancer. Creating environmental and sustainable solutions for lithium-ion battery technology. Improving the safety and efficacy of gene editing and understanding the mechanisms of DNA repair to potentially cure diseases. Discovering the most distant and massive galaxies that have reshaped our understanding of early Universe star formation and supermassive black holes.

Dec 11, 2024 | mdanderson.org | Lauren Averett Byers

Lauren Averett Byers, M.D., professor of Thoracic/Head & Neck Medical Oncology at The University of Texas MD Anderson Cancer Center, has received the 2025 Edith and Peter O’Donnell Award in Medicine from the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST).

Nov 18, 2024 | nature.com | Allison Stewart |Alexander J. Lazar |Lauren Averett Byers

AbstractDelta-like Ligand 3 (DLL3) targeting therapies are promising in small cell lung cancer (SCLC) treatment. However, DLL3 expression in SCLC and other neuroendocrine neoplasms (NEN) is heterogeneous and not well characterized. We describe the landscape of DLL3 at the mRNA and protein levels across SCLC, large cell neuroendocrine carcinoma (LCNEC), and non-small cell lung cancer. Additionally, we explore its expression in extra-pulmonary NEN (EP-NEN) using a standardized DLL3 IHC assay.

Jun 25, 2024 | ascopost.com | Alice Goodman |Lauren Averett Byers

Consolidation therapy with the PD-L1 antibody durvalumab after chemoradiotherapy extended survival in patients with limited-stage small cell lung cancer (SCLC) compared with standard-of-care chemoradiotherapy alone, according to the first planned interim analysis of the phase III ADRIATIC trial presented at the 2024 ASCO Annual Meeting by David R.